Abstract Library

#3106 Advanced small intestine well-differentiated neuroendocrine tumors (WD-SiNET): A survey of practice on 3rd line treatment

Introduction: Selection of third-line treatment after somatostatin analogues (SSA) and Peptide Receptor Radionuclide Therapy (PRRT) for WD-SiNETs remains challenging.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lamarca A

Authors: Lamarca A, Cives M, de Mestier L, Crona J, Spada F,

Keywords: small bowel, well-differentiated, third-line, everolimus, IFN, chemotherapy, liver embolisation, multidisciplinary, survey, decision making,

#3104 Molecular profiling of well-differentiated neuroendocrine tumors: Role of ctDNA

Introduction: Tumor molecular profiling has proven relevant for the clinical management of cancer. Circulating tumor DNA (ctDNA) may be a useful surrogate of tumor tissue when this is insufficient for analysis.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lamarca A

Authors: Lamarca A, Frizziero M, Barriuso J, Kapacee Z, Mansoor W,

Keywords: ctDNA, well-differentiated, neuroendocrine,

#3005 Comparison between Tang and WHO 5th Edition Grade Classification for Goblet Cell Adenocarcinomas

Introduction: Appendiceal GCAs (previously Goblet Cell Carcinoids) are composed of cells with secretory phenotypes. Several grading systems to predict behaviour are available (e.g.Tang). The latest WHO 5th edition adopted a grading system similar to colon adenocarcinomas.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Barriuso J, Nonaka D, Nagaraju R, Shenjere P, Lamarca A,

Keywords: goblet cell adenocarcinomas, tang, who grade,

#2993 Proposal of New Imaging Criteria for Evaluating the Response of Liver Metastases to Systemic Treatments in Digestive Neuroendocrine Tumors (NET) as an Alternative to RECIST 1.1

Introduction: RECIST 1.1 criteria have been challenged for the evaluation of treatment response in NET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: de Mestier L, Dromain C, Lamarca A, La Salvia A, Op de Beeck B,

Keywords: imaging criteria, response evaluation, CT scan,

#2927 Systemic Chemotherapy for Inoperable Goblet Cell Adenocarcinomas (GCAs) and the Role of Anti-EGFR Antibodies

Introduction: Appendiceal GCAs (previously Goblet Cell Carcinoids) have variable behaviour. Systemic chemotherapy (Chemo) is often extrapolated from colon cancer. KRAS mutations (KRAS-mut) are rare and more often present in Tang-C/high grade. The role of anti-EGFR antibodies (MoAb) is unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Barriuso J, Martin A, Chakrabarty B, Burghel G, Lamarca A,

Keywords: goblet cell adenocarcinomas, chemotherapy, anti-egfr,